CA2691736A1 - Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human - Google Patents

Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human Download PDF

Info

Publication number
CA2691736A1
CA2691736A1 CA002691736A CA2691736A CA2691736A1 CA 2691736 A1 CA2691736 A1 CA 2691736A1 CA 002691736 A CA002691736 A CA 002691736A CA 2691736 A CA2691736 A CA 2691736A CA 2691736 A1 CA2691736 A1 CA 2691736A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
lopinavir
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002691736A
Other languages
English (en)
French (fr)
Inventor
Brian P. Kearney
Anita A. Mathias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2691736A1 publication Critical patent/CA2691736A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002691736A 2007-06-29 2008-06-26 Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human Abandoned CA2691736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94732507P 2007-06-29 2007-06-29
US60/947,325 2007-06-29
PCT/US2008/068351 WO2009006203A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
CA2691736A1 true CA2691736A1 (en) 2009-01-08

Family

ID=39817166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002691736A Abandoned CA2691736A1 (en) 2007-06-29 2008-06-26 Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human

Country Status (21)

Country Link
US (4) US20110009411A1 (cg-RX-API-DMAC7.html)
EP (1) EP2167089A1 (cg-RX-API-DMAC7.html)
JP (3) JP5547067B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100028656A (cg-RX-API-DMAC7.html)
CN (2) CN103356622A (cg-RX-API-DMAC7.html)
AP (1) AP2490A (cg-RX-API-DMAC7.html)
AR (1) AR067184A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008270634B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813955A2 (cg-RX-API-DMAC7.html)
CA (1) CA2691736A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251236A2 (cg-RX-API-DMAC7.html)
EA (1) EA200971096A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP109889A (cg-RX-API-DMAC7.html)
IL (1) IL202745A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013828A (cg-RX-API-DMAC7.html)
NZ (1) NZ582089A (cg-RX-API-DMAC7.html)
SG (1) SG182228A1 (cg-RX-API-DMAC7.html)
TW (1) TW200916103A (cg-RX-API-DMAC7.html)
UA (1) UA103881C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009006203A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000468B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20080313A2 (en) * 2005-12-30 2008-11-30 Gilead Sciences Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP4566670A3 (en) 2006-07-07 2025-08-27 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SG10201501782UA (en) 2006-09-12 2015-05-28 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
AP3915A (en) * 2007-02-23 2016-11-29 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
KR20100040892A (ko) * 2007-06-29 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
HRP20151357T1 (hr) 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
ES2582877T3 (es) * 2010-04-09 2016-09-15 Bristol-Myers Squibb Holdings Ireland Formulaciones de sulfato de atazanavir con un efecto de pH mejorado
WO2012088178A1 (en) * 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
EP3750544B1 (en) 2011-11-30 2025-03-05 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AU2013225981A1 (en) * 2012-03-01 2014-10-02 Gilead Sciences, Inc. Spray dried formulations
CA2878699C (en) 2012-08-03 2018-09-11 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN107674086B (zh) 2012-12-21 2020-03-31 吉利德科学公司 多环-氨基甲酰基吡啶酮化合物及其药物用途
NO2865735T3 (cg-RX-API-DMAC7.html) 2013-07-12 2018-07-21
PL3252058T3 (pl) 2013-07-12 2021-07-19 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
NO2717902T3 (cg-RX-API-DMAC7.html) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
HK1249103B (en) 2015-04-02 2020-02-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
KR100665919B1 (ko) * 2002-11-20 2007-03-08 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 및 ｈｉｖ 인테그라제 저해제로서의그의 용도
US20060111933A1 (en) * 2003-10-09 2006-05-25 Steven Wheeler Adaptive medical decision support system
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP3287130A1 (en) * 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
HRP20080313A2 (en) * 2005-12-30 2008-11-30 Gilead Sciences Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
EP4566670A3 (en) * 2006-07-07 2025-08-27 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SG10201501782UA (en) * 2006-09-12 2015-05-28 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
KR20100040892A (ko) * 2007-06-29 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
HRP20151357T1 (hr) * 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
ZA201000468B (en) 2011-06-29
JP5547067B2 (ja) 2014-07-09
CN101743004A (zh) 2010-06-16
AP2490A (en) 2012-10-04
JP2013199494A (ja) 2013-10-03
US20140343062A1 (en) 2014-11-20
WO2009006203A1 (en) 2009-01-08
AP2009005083A0 (en) 2009-12-31
CO6251236A2 (es) 2011-02-21
EP2167089A1 (en) 2010-03-31
TW200916103A (en) 2009-04-16
CN103356622A (zh) 2013-10-23
AU2008270634B2 (en) 2014-01-16
BRPI0813955A2 (pt) 2017-05-09
KR20100028656A (ko) 2010-03-12
IL202745A0 (en) 2010-06-30
ECSP109889A (es) 2010-03-31
JP5769762B2 (ja) 2015-08-26
MX2009013828A (es) 2010-03-10
EA200971096A1 (ru) 2010-08-30
AR067184A1 (es) 2009-09-30
UA103881C2 (ru) 2013-12-10
SG182228A1 (en) 2012-07-30
NZ582089A (en) 2013-01-25
US20170136000A1 (en) 2017-05-18
AU2008270634A1 (en) 2009-01-08
US20110009411A1 (en) 2011-01-13
US20090093482A1 (en) 2009-04-09
JP2010532373A (ja) 2010-10-07
JP2015143277A (ja) 2015-08-06

Similar Documents

Publication Publication Date Title
AU2008270634B2 (en) Therapeutic compositions and the use thereof
AU2008270630B2 (en) Therapeutic compositions and the use thereof
EP1458447B1 (en) Combination of cytochome p 450 dependent protease inhibitors
AU2006332664B2 (en) Methods for improving the pharmacokinetics of HIV integrase inhibitors
HK1156259A (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130403

FZDE Discontinued

Effective date: 20170710